| Name | Title | Contact Details |
|---|
Pulmotect has developed PUL-042, an inhaled therapeutic which aims to boost the body`s innate immune system resulting in highly-targeted lung protection against all major classes of pathogens including bacteria, fungi, and viral pathogens.
Leap is developing novel drugs to change the practice of cancer medicine
Delix Therapeutics is applying modern tools of pharmaceutical development to some of natures most ancient therapies, psychedelics.
Gliknik Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders.
PAR Management is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.